Calliditas Q1 report, January - March 2024

JANUARY - MARCH 2024 (COMPARED TO JANUARY - MARCH 2023) JANUARY -MARCH 2024(COMPARED TO JANUARY -MARCH 2023 ) "In Q1 we generated another record quarter in terms of demand with 705 enrollments and 354 new prescribers. We are very excited over this positive trend, and we continue to see strong demand in Q2 ." - CEO Renée Aguiar-Lucander. KEY TAKEAWAYS FROM Q1, 2024                              KEY EVENTS AFTER THE REPORTING PERIOD                                    KEY...

JANUARY - MARCH 2024 (COMPARED TO JANUARY - MARCH 2023)

"In Q1 we generated another record quarter in terms of demand with 705 enrollments and 354 new prescribers. We are very excited over this positive trend, and we continue to see strong demand in Q2." - CEO Renée Aguiar-Lucander.

KEY TAKEAWAYS FROM Q1, 2024                             

KEY EVENTS AFTER THE REPORTING PERIOD                                   

KEY EVENTS UPCOMING 6 MONTHS                                 ��  

Outlook for 2024: Unchanged

Calliditas expects continued revenue growth:

Total net sales from the Nefecon franchise, including milestones, are estimated to be USD 150-180 million for the year ending December 31, 2024.

Investor Presentation:

May 23, 202414:30 CET

Link to webcast: Calliditas Therapeutics Q1 Report 2024 (financialhearings.com)

To participate via conference call register via this link:  Call Access (financialhearings.com)

For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: [email protected]

The information in the report is information that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact person set out above, on May 23, 2024, at 7:00 a.m. CET.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/calliditas-therapeutics/r/calliditas-q1-report--january---march-2024,c3986496

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/calliditas-q1-report-january--march-2024-302153828.html